Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.69 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699682 | 0.96 | CDK1 (0.64) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL8649826 | 0.95 | CDK1 (0.66) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL9621810 | 0.95 | CDK1 (0.66) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL6358258 | 0.94 | CDK1 (0.62) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL11571981 | 0.94 | CDK1 (0.61) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL983823 | 0.93 | CDK1 (0.64) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL9621529 | 0.93 | CDK1 (0.69) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL27385359 | 0.91 | CDK1 (0.61) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL1879409 | 0.91 | CDK1 (0.66) | CDK1CCNB1LDHACA2CA9 | |
| SCHEMBL8051998 | 0.91 | CDK1 (0.66) | CDK1CCNB1LDHACA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107412165-A | A kind of preparation method of AM Bison | 上海上药新亚药业有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-7807418-B2 | Method for producing hybrid polyketide synthases | BIOTICA TECHNOLOGY LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| EP-2182067-A2 | Hybrid polyketide synthases | Biotica Technology Limited (GB) | 2010-05-05 | — | — | EP | disclosed |
| EP-0910633-B1 | Hybrid polyketide synthase I gene | BIOTICA TECH LTD (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20050272692-A1 | Sucrose ester compounds useful as fungicides | FARONE WILLIAM A | 2005-12-08 | — | — | US | disclosed |
| EP-1602727-A2 | Novel erythromycins and process for their preparation | Biotica Technology Limited (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6960453-B1 | Hybrid polyketide synthases combining heterologous loading and extender modules | BIOTICA TECHNOLOGY LIMITED (GB) | 2005-11-01 | — | — | US | disclosed |
| EP-0909327-B1 | ERYTHROMYCINS AND PROCESS FOR THEIR PREPARATION | BIOTICA TECH LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20050089982-A1 | Polyketides and their synthesis | LEADLAY PETER F (GB) | 2005-04-28 | — | — | US | disclosed |
| CN-1179046-C | Erythromycins and process for their preparation | �ݰµٿ���������˾ | 2004-12-08 | — | — | CN | disclosed |
| US-6437151-B2 | FERMENTATION; CULTURE PRODUCT | BIOTICA TECHNOLOGY LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| US-20020004487-A1 | Novel erythromycins and process for their preparation | BIOTICA TECHNOLOGY LIMITED (GB) | 2002-01-10 | — | — | US | disclosed |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | LEADLAY PETER FRANCIS (GB) | 2001-08-23 | — | — | US | disclosed |
| US-6271255-B1 | USEFUL AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS IN INFECTIONS IN MAMMALS, FISH, AND BIRDS | BIOTICA TECHNOLOGY LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| CN-1229438-A | Erythromycins and process for their preparation | BIOTICA TECH LTD (GB) | 1999-09-22 | — | — | CN | disclosed |
| EP-0910633-A2 | POLYKETIDES AND THEIR SYNTHESIS | Biotica Technology Limited (GB) | 1999-04-28 | — | — | EP | disclosed |
| EP-0909327-A2 | ERYTHROMYCINS AND PROCESS FOR THEIR PREPARATION | Biotica Technology Limited (GB) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998001546-A2 | POLYKETIDES AND THEIR SYNTHESIS | BIOTICA TECHNOLOGY LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001571-A2 | ERYTHROMYCINS AND PROCESS FOR THEIR PREPARATION | BIOTICA TECHNOLOGY LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
| US-4151304-A | WATER IN OIL EMULSIONS, SUCCINIC HALF ESTERS OF SUCROSE | LEVER BROTHERS COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272692-A1 | Sucrose ester compounds useful as fungicides | ERG28, MGAM, CYP51A1 | CDK1 4340/4885CCNB1 4655/4885LDHA 2087/4885 |
| US-20020004487-A1 | Novel erythromycins and process for their preparation | MRPL21, RPL13, RPS3A | CDK1 1645/4885CCNB1 1175/4885LDHA 1665/4885 |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | COASY, RPL13, DCXR | CDK1 3082/4885CCNB1 1777/4885LDHA 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.